 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || TAK-881 / Takeda
Enrollment open: A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases (clinicaltrials.gov) - Nov 8, 2024
P3, N=39, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting
- | TAK-881 / Takeda
Trial completion date, Trial primary completion date: A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases (clinicaltrials.gov) - Jul 1, 2024
P3, N=39, Not yet recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Trial completion date: May 2027 --> Jan 2029 | Trial primary completion date: May 2027 --> Jan 2029
- || TAK-881 / Takeda
Enrollment change: A Study of TAK-881 in Healthy Adults (clinicaltrials.gov) - Jan 12, 2024
P1, N=24, Completed, Sponsor: Takeda
Trial completion date: May 2027 --> Jan 2029 | Trial primary completion date: May 2027 --> Jan 2029 N=80 --> 24
- |||| TAK-881 / Takeda
Enrollment open, Adverse events: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases (clinicaltrials.gov) - Dec 18, 2023
P2/3, N=71, Recruiting, Sponsor: Takeda
N=80 --> 24 Not yet recruiting --> Recruiting
- |||| TAK-881 / Takeda
New P3 trial: A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases (clinicaltrials.gov) - Oct 10, 2023
P3, N=39, Not yet recruiting, Sponsor: Takeda
- ||| TAK-881 / Takeda
Trial completion date, Trial primary completion date, Adverse events: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases (clinicaltrials.gov) - Sep 26, 2023
P2/3, N=71, Not yet recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting Trial completion date: Apr 2025 --> Sep 2026 | Trial primary completion date: Apr 2025 --> Feb 2026
- |||| TAK-881 / Takeda
Trial initiation date, Adverse events: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases (clinicaltrials.gov) - Jun 29, 2023
P2/3, N=61, Not yet recruiting, Sponsor: Takeda
Trial completion date: Apr 2025 --> Sep 2026 | Trial primary completion date: Apr 2025 --> Feb 2026 Initiation date: Mar 2023 --> Oct 2023
- |||||||| TAK-881 / Takeda
New P2/3 trial, Adverse events: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases (clinicaltrials.gov) - Mar 6, 2023
P2/3, N=61, Not yet recruiting, Sponsor: Takeda
- ||| TAK-881 / Takeda
Trial completion: A Study of TAK-881 in Healthy Adults (clinicaltrials.gov) - Apr 28, 2022
P1, N=80, Completed, Sponsor: Takeda
Initiation date: Mar 2023 --> Oct 2023 Active, not recruiting --> Completed
- || TAK-881 / Takeda
Enrollment closed, Enrollment change: A Study of TAK-881 in Healthy Adults (clinicaltrials.gov) - Feb 28, 2022
P1, N=80, Active, not recruiting, Sponsor: Takeda
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=24 --> 80
- || TAK-881 / Takeda
Enrollment open: A Study of TAK-881 in Healthy Adults (clinicaltrials.gov) - Nov 26, 2021
P1, N=24, Recruiting, Sponsor: Takeda
Recruiting --> Active, not recruiting | N=24 --> 80 Not yet recruiting --> Recruiting
- || TAK-881 / Takeda
New P1 trial: A Study of TAK-881 in Healthy Adults (clinicaltrials.gov) - Sep 27, 2021
P1, N=24, Not yet recruiting, Sponsor: Takeda